Rituximab, a lower-cost treatment, may be as effective at managing RRMS as the approved therapy Ocrevus, a new study from ...

KRISHNAGIRI: A 15-year-old girl from Hosur who has been diagnosed with an autoimmune disease is in need of a critical ...

Although the study was conducted at a single center, patients achieved clinical improvement and cessation of steroid therapy.

However, recent advancements in antibody absorption columns and drugs such as Rituximab that target B cells, have improved ...

Patients with pemphigus in complete remission had a reduced risk of relapse after receiving an additional rituximab infusion at month 6, according to a study.In the RITUX 3 trial, patients with ...

The following is a summary of “Rituximab combined with intravenous immunoglobulin in autoimmune diseases: a systematic review,” published in the March 2025 issue of Advances in Rheumatology by ...

ECHELON-3 (NCT04404283) principal investigator Craig A. Portell, MD, speaks to the significance of this triplet approval from ...

Roche has secured approval from the European Commission (EC) for Columvi (glofitamab) plus gemcitabine and oxaliplatin (GemOx ...

The results of two controlled trials, now published in the January 2010 issue of Arthritis and Rheumatism, suggest that treatment with the B-cell depleting agent, rituximab, lowers the response to ...

To stabilize this condition we started rituximab therapy immediately after the third cycle of immunoadsorption, with 375 mg/m 2 rituximab being administered intravenously once weekly for 4 weeks.

Innovative polatuzumab vedotin plus R-CHP therapy reshapes treatment of older adult patients with diffuse large B-cell lymphoma.

Calquence in combination with bendamustine and rituximab has been recommended for approval in the European Union, EU, for ...